CNS Pharmaceuticals enhances equity plan through restatement
CNS Pharmaceuticals, Inc. has amended and restated its 2020 Equity Plan, effective from multiple past and future dates, with stockholder approval pending for the final amendment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed